FDA
-
-
-
-
-
-
-
Novo Nordisk launches once-weekly basal insulin Awiqli nationwide
-
-
-
-
-
-
-
FDA proposes to exclude semaglutide, tirzepatide from compounding list
-
-
-
-
-
-
-
FDA approves Novo Nordisk's higher-dose Wegovy injection
-
-
-
-
-
-
-
Hims shares jump on deal to offer Novo's Wegovy, Ozempic on its platform
-
-
-
-
-
-
-
FDA flags Novo Nordisk Wegovy pill advertisement as misleading
-
-
-
-
-
-
-
Hims & Hers stock falls after FDA warns against illegal copycat drugs
-
-
-
-
-
-
-
Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs
-
334,840 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


